ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2237

Assessment Of Wage and Salary Growth In Patients With Rheumatoid Arthritis (RA)

Martin J. Bergman1, Gourab De2, Arijit X. Ganguli3, James Signorovitch4 and Yanjun Bao5, 1Taylor Hospital, Ridley Park, PA, 2Analysis Group, Inc., New York, NY, 3AbbVie, Inc., North Chicago, IL, 4Analysis Group, Inc., Boston, MA, 5AbbVie Inc., North Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Disability and rheumatoid arthritis (RA), Workforce

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: RA negatively impacts patients’ work outcomes. Treatment with tumor necrosis factor inhibitors (anti-TNFs) has been associated with improved work productivity and stability in RA. However, no studies have assessed the impact of anti-TNF treatment on changes in RA patients’ income over time. Our study aims to compare growth of wage and salary income over time between employees with RA treated with anti-TNFs and those treated with methotrexate (MTX).

Methods: Adults with ≥ 1 RA diagnosis (ICD-9 CM: 714.0) were identified in a large-scale U.S. claims database (OptumInsight, 1998-2011). Patients were stratified into the following two groups: 1) those who filled ≥1 prescriptions for anti-TNFs, either with or without MTX (index date defined as the date of the first anti-TNF prescription) and (2) those who filled prescriptions for MTX monotherapy (index date randomly selected). During the 6-month baseline period preceding their index prescription, patients in both groups were required to have continuous health plan enrollment and to be free of anti-TNF prescriptions. The primary study outcome was annual wage or salary income (US dollars) observed from index year up to five years of follow-up (more than 90% of patients were lost to follow-up after five years). The effect of treatment on wage and salary income growth over time, starting from the same initial annual income, was assessed using a multivariable generalized linear model with adjustment for index year, age, region, gender, Charlson Comorbidity Index, health plan and total RA-related cost in the baseline period. Based on this regression model, income growth was compared to expected wage growth for the general population based on the best and worst 5-year runs of national wage data reported by Bureau of Labor Statistics during 1998-2011.

Results: The study included 1,866 patients in the MTX cohort and 1,848 patients in the anti-TNF cohort. At the index date, the MTX and anti-TNF cohorts had, respectively, average ages of 48.4 and 46.1 years, 64.8% and 62.0% females and average annual wage and salary income of $51,554 and $56,674. After adjusting for baseline characteristics, wage and salary incomes for patients in the anti-TNF cohort increased by 2.8% (CI: 1.9% – 3.6%) per year, significantly greater (p<0.05) than the 0.6% (CI: -0.2% – 1.4%) per year increase estimated for the MTX group. Based on this regression analysis, the average growth in wage and salary income for an RA patient treated with anti-TNF was consistent with that of the general population. In contrast, wage and salary growth for an RA patient treated with MTX was significantly lower than expected in the general population (p<0.05).

Conclusion: Compared to MTX monotherapy, anti-TNF treatment is associated with a greater rate of annual income growth among employees with RA.  In the anti-TNF group, income growth rate is comparable to the general employed population norm.

 


Disclosure:

M. J. Bergman,

AbbVie,

5;

G. De,

AbbVie,

5;

A. X. Ganguli,

AbbVie,Inc.,

1,

AbbVie, Inc.,

3;

J. Signorovitch,

AbbVie,

5;

Y. Bao,

AbbVie, Inc.,

1,

AbbVie, Inc.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-wage-and-salary-growth-in-patients-with-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology